# Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

*PRI Rank #1 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-1*

| Field | Value |
| --- | --- |
| Rank | #1 |
| 18m citations | 369 |
| Journal | The Lancet |
| Year | 2024 |
| DOI | 10.1016/s0140-6736(23)02268-7 |
| Corresponding authors | Jeffrey S. Weber |
| Institution | NYU Langone Health, United States |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1016/s0140-6736(23)02268-7](https://doi.org/10.1016/s0140-6736(23)02268-7)

## Topics

mRNA-4157 · mRNA-4157 · pembrolizumab · personalized neoantigen vaccine · resected melanoma · KEYNOTE-942 · Phase II clinical trial · combination immunotherapy · personalized neoantigen vaccine · Adjuvant therapy · PD-1 inhibition · neoantigen · mRNA vaccine · recurrence-free survival

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```